Stock Evaluator: Pfizer Inc. (PFE)

4,154 followers

Pfizer Inc. PFE

$25.01 0.10 0.40%
July 31, 2026 4:01:49 PM EST November 10, 2021 Volume: 45,053,147
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NYSE | DELAYED PRICE
SECTOR INDUSTRY
Health Care Pharmaceuticals

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Commentary & Analysis


Financial Summary

Share Statistics PFE Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $141,973.2 $569.9 98%
Shares Out (Mil) 5,731.0 44.8 99%
Institutional Ownership 100.0% 84.6% 99%
Float (Mil) 5,691.6 45.1 99%
Beta 0.31 0.67 18%
Avg Daily Volume (000s) 36,555 294 99%
Price Change
(52-week)
2.5% 65.2% 48%
Growth PFE Industry
Median
Percentile
(All Stocks)
Sales (5yr) 8.5% 6.7% 52%
Net Income (5yr) (3.2%) (2.0%) 35%
EPS (5yr) (3.5%) 14.9% 26
Dividends (5yr) 2.5% 0.0% 88%
Cash Flow (5yr) (26.0%) (14.9%) 24%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 20 25 24
Current EPS $0.682 $2.945 $2.832
Month Ago EPS $0.679 $2.959 $2.829
# Rev Up 1 1 0
# Rev Down 1 1 2
Three Months Ago EPS $0.680 $2.964 $2.824
Year/Year Chg 45.1% 116.5% 78.3%
Financials PFE Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $63,315 $230 98%
Net Income (TTM) (Mil) $7,491 ($11) 98%
EPS (TTM) $1.317 ($0.600) 65%
Operating Cash Flow (TTM) (Mil) $11,984 ($6) 98%
Net Cash Flow (TTM) (Mil) na $4 na
Long-Term Debt (Q1) (Mil) $60,840 $7 99%
Enterprise Value (Q1) (Mil) $196,320 $493 98%
Valuation PFE Industry
Median
Percentile
(All Stocks)
P/B 1.58 2.89 41%
P/E 19.0 20.6 47%
Dividend Yield 6.9% 0.0% 97%
PEG (5yr hist) 6.6 1.1 90%
Ratios PFE Industry
Median
Percentile
(All Stocks)
Gross Margin 74.8% 65.9% 85%
Net Margin 11.8% (0.2%) 67%
ROA 3.6% (25.5%) 65%
ROE 8.3% (21.4%) 52%
Liabilities to Assets 56.5% 35.5% 49%
F-Score 5 3 51%

Pfizer Inc. did not pass any screens on 7/30/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors